Get the Stockscreener App
3.47
9.49%
0.31
After Hours:
3.43
-0.04
-1.15%
Immunitybio Inc stock is traded at $3.47, with a volume of 6.18M.
It is up +9.49% in the last 24 hours and up +29.10% over the past month.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.
See More
Previous Close:
$3.16
Open:
$3.18
24h Volume:
6.18M
Relative Volume:
0.82
Market Cap:
$2.50B
Revenue:
$1.31M
Net Income/Loss:
$-597.65M
P/E Ratio:
-3.5773
EPS:
-0.97
Net Cash Flow:
$-425.62M
1W Performance:
+10.90%
1M Performance:
+29.10%
6M Performance:
-34.47%
1Y Performance:
-1.70%
1-Day Range:
$3.08
$3.49
1-Week Range:
$2.91
$3.72
52-Week Range:
$2.28
$10.53
Immunitybio Inc Stock (IBRX) Company Profile
Name
Immunitybio Inc
Sector
Industry
Phone
(844) 696-5235
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
3.47 | 2.50B | 1.31M | -597.65M | -425.62M | -0.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.67B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 74.97B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.50B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 29.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Initiated | BTIG Research | Buy |
| May-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-03-22 | Initiated | Jefferies | Buy |
Immunitybio Inc Stock (IBRX) Latest News
Here’s Why ImmunityBio, Inc. (IBRX) Will Double in 2025 - Yahoo Finance
ImmunityBio (NASDAQ:IBRX) Trading Up 17.2%Still a Buy? - MarketBeat
ImmunityBio and BeiGene partner on Phase III trial of NSCLC treatment combo - Yahoo Finance
ImmunityBio Shares Rise After Collaboration, Supply Agreement With BeiGene - MarketWatch
Why ImmunityBio Stock is Gaining Momentum - TipRanks
ImmunityBio Partners With BeiGene to Conduct Phase 3 Trial of Lung Cancer Combination Therapy - Marketscreener.com
ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer - Business Wire
ImmunityBio's (IBRX) "Buy" Rating Reaffirmed at D. Boral Capital - MarketBeat
ImmunityBio (NASDAQ:IBRX) Earns Buy Rating from D. Boral Capital - MarketBeat
ImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ - BioSpace
ImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA - Business Wire
ImmunityBio (NASDAQ:IBRX) Trading Down 4.2%What's Next? - MarketBeat
ImmunityBio: Despite Anktiva's Clinical Promise, Remains A Difficult Investment (IBRX) - Seeking Alpha
ImmunityBio (NASDAQ:IBRX) Stock Quotes, Forecast and News Summary - Benzinga
ImmunityBio, Inc. (IBRX) Stock: An Under $5 Gem with Biggest Upside Potential - Insider Monkey
IBRX Stock Soars on Completing Filing for Cancer Therapy in EU & UK - MSN
Why Did Immunitybio (IBRX) Go Down on Friday? - MSN
IonQ, H&E Equipment Services And ImmunityBio Are Among Top Mid Cap Gainers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio? - Benzinga
Why ImmunityBio, Inc. (IBRX) Dominated Last Week’s Rally - Insider Monkey
ImmunityBio, Inc. (NASDAQ:IBRX) Short Interest Update - MarketBeat
ImmunityBio (NASDAQ:IBRX) Shares Gap UpTime to Buy? - MarketBeat
JPMorgan Chase & Co. Has $4.24 Million Stock Holdings in ImmunityBio, Inc. (NASDAQ:IBRX) - Defense World
D. Boral Capital Reaffirms “Buy” Rating for ImmunityBio (NASDAQ:IBRX) - Defense World
ImmunityBio stock gains 15% amid regulatory updates - MSN
ImmunityBio (NASDAQ:IBRX) Stock Price Down 5.2%What's Next? - MarketBeat
ImmunityBio: Making Its Next Strikes After Bladder Cancer Approval (Upgrade) (NASDAQ:IBRX) - Seeking Alpha
ImmunityBio Target of Unusually Large Options Trading (NASDAQ:IBRX) - MarketBeat
ImmunityBio (NASDAQ:IBRX) Shares Up 6.3%Here's Why - MarketBeat
ImmunityBio (NASDAQ:IBRX) Receives "Buy" Rating from D. Boral Capital - MarketBeat
Investors Purchase Large Volume of Call Options on ImmunityBio (NASDAQ:IBRX) - Defense World
Why ImmunityBio, Inc. (IBRX) Is Skyrocketing - MSN
ImmunityBio Stock Trading Higher On Updates From Bladder Cancer Trials: Details - Benzinga
ImmunityBio stock gains 15% amid regulatory updates (IBRX:NASDAQ) - Seeking Alpha
ImmunityBio Shares Climb After Company Previews FY25 Regulatory Advances - MarketWatch
ImmunityBio shares surge following progress in FDA discussions By Investing.com - Investing.com Canada
ImmunityBio shares surge following progress in FDA discussions - Investing.com
Symbotic, DouYu International, Sezzle And Other Big Stocks Moving Higher On Thursday - Benzinga
Anktiva targets expanded indication in US and global approvals in EU and UK - Urology Times
D. Boral Capital Reaffirms "Buy" Rating for ImmunityBio (NASDAQ:IBRX) - MarketBeat
ImmunityBio Provides Regulatory Update on Global Submission for ANKTIVA + BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ in Europe and United Kingdom - BioSpace
ImmunityBio Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the Agency - BioSpace
How to spot and prevent hypothermia - AOL
Why ImmunityBio, Inc. (IBRX) Is the Top Small Cap Stock to Buy with the Highest Upside Potential - MSN
ImmunityBio (NASDAQ:IBRX) Shares Down 5.2%Time to Sell? - MarketBeat
BTIG initiates ImmunityBio stock with Buy rating, cites potential of planned/underway studies - Investing.com Nigeria
ImmunityBio (NASDAQ:IBRX) Sets New 12-Month LowHere's What Happened - MarketBeat
BTIG initiates ImmunityBio stock with Buy rating, cites potential of planned/underway studies By Investing.com - Investing.com South Africa
ImmunityBio (NASDAQ:IBRX) Earns Buy Rating from Analysts at BTIG Research - MarketBeat
Principal Financial Group Inc. Sells 28,706 Shares of ImmunityBio, Inc. (NASDAQ:IBRX) - Defense World
Immunitybio Inc Stock (IBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.46%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):